Tsuyoshi Chiwata

Pharma Two B Ltd. operates as a biopharmaceutical company which focuses on developing treatments for Parkinson’s disease. The firm focuses on Fixed-Dose-combinations of two or more drugs with synergistic effects, providing clinical value and regulatory pathways. The company was founded by Ehud Marom and Nurit Livnah in December 2007 and is headquartered in Rehovot, Israel.

Inanovate, Inc. provides protein screening services. Its product include Bio-ID, a multiplexed protein quantification platform which, in real-time, measures protein concentrations from matrices. The company was founded by David Alexander Ure and David J Arslanian in 2007 and is headquartered in Sioux Falls, SD.

New England Eye Center offers a full range of ophthalmology services. It specializes in cornea, external disease, and cataracts; glaucoma; oculoplastics; pediatric ophthalmology; retinal and macular diseases; vision rehabilitation; uveitis and immunology; pediatric optometry; and vision correction surgery. The company is headquartered in Boston, MA.

Safar Partners LLC (Safar Partners) is a venture capital firm founded in 2019 by Nader Motamedy. The firm is headquartered in Cambridge, Massachusetts.

Caspian Private Equity LLC is a private equity firm founded in 2008.The firm is headquartered in New York.

Palvella Therapeutics, Inc. operates as a rare disease biopharmaceutical company. It develops and commercializes pathogenetically targeted therapies for rare genodermatoses with no approved treatments. Its products include QTORIN, PTX-022, PTX-367, and PTX-014. The company was founded by Wesley H. Kaupinen in 2015 and is headquartered in Wayne, PA.

Valera Pharmaceuticals, Inc. develops and commercializes products for the treatment of urology and endocrine conditions, diseases and disorders. The Company was founded in 1972 and is located in Cranbury, NJ.

Bimeda, Inc. manufactures veterinary pharmaceuticals and animal health care products. The company has operations in the United Kingdom, Canada, the United States, Mexico, and Ireland. The firm was founded in 1997 and is headquartered in Oakbrook, IL

Elan Pharmaceuticals LLC develops and manufactures pharmaceutical products. It specializes in treatment of neurological and autoimmune diseases. The firm's drugs are used in the treatment of for Alzheimer's, Parkinson's, and rheumatoid arthritis diseases. The company is headquartered in South San Francisco, CA.

Signet Healthcare Partners LLC (Signet Healthcare Partners) is a private equity/venture capital subsidiary of Sanders Morris Harris Group Private Equity founded in 1998. The firm is headquartered in New York.

Icon Bioscience, Inc. develops and markets ophthalmic pharmaceuticals. It develops specialty pharmaceuticals targeting ophthalmic indications including macular edema, glaucoma, age-related macular degeneration and cataract surgery. The firm's pipeline includes IBI-10090, IBI-20089, IBI-60089, and IBI-80090. The company was founded by Vernon G. Wong and is headquartered in Newark, CA.

Oceana Therapeutics, Inc. manufactures pharmaceuticals and medical devices. It develops and commercializes therapeutics with a focus on colorectal, gastroenterology, and urological diseases. The firm provides Deflux that is used for the treatment of Vesicoureteral reflux, urological conditions and Solesta which is used for the treatment of fecal incontinence. The company was founded in 2008 and is headquartered in Edison, NJ.

Roberts Pharmaceutical Corp. provides pharmaceutical products. It offers medicines for cardiovascular, gynecology. The company is headquartered in Eatontown, NJ.

Aurion Biotech, Inc. is a clinical-stage biotech company with offices in multiple locations. Aurion Biotech has initiated clinical trials in the US in 2023. The company is based in Seattle, WA. The company's mission is to restore vision to millions of patients with life-changing regenerative therapies. Aurion Biotech has received the prestigious Prix Galien award for best start-up in biotech. The company's first candidate is an off-the-shelf, clinically validated cell therapy for corneal care, which has received regulatory approval. The company is privately held and backed by leading investors, including Deerfield, Alcon, Petrichor, Flying L Partners, Falcon Vision/KKR, and Visionary Ventures. Greg Kunst has been the CEO of the company since 2021.